A new treatment for sickle cell disease begins with a patient’s own blood-forming stem cells. In a laboratory, clinicians use CRISPR gene editing to change those cells. After chemotherapy clears space in the bone marrow, the edited cells are returned to the patient, where they can produce red blood cells with more fetal hemoglobin—a form of hemoglobin that helps prevent sickling.
The treatment, called exagamglogene autotemcel and sold as Casgevy, became the first CRISPR-based therapy approved by the U.S. Food and Drug Administration in December 2023. It is approved for people aged 12 and older with sickle cell disease and a history of recurrent vaso-occlusive crises, the episodes in which sickled cells obstruct blood flow and can cause severe pain.
It is a landmark not because gene editing has made the disease disappear, but because it has given some patients a new way to address one of its central biological causes.
Changing the instructions inside blood stem cells
Sickle cell disease is inherited. A change in the gene that helps make adult hemoglobin can cause red blood cells to become rigid and crescent-shaped. These cells may break down sooner than usual or block small blood vessels, contributing to anemia, pain crises and damage to organs over time.
Casgevy takes a different route from a medicine that must be taken regularly. Doctors collect a patient’s blood-forming stem cells and use CRISPR-Cas9 to edit a control region linked to the BCL11A gene. That change is intended to increase production of fetal hemoglobin in the patient’s red blood cells. Fetal hemoglobin is normally switched down after infancy; increasing it can reduce the tendency of red blood cells to sickle.
Because the cells come from the patient, the approach is often described as an autologous cell therapy. The editing happens outside the body, not through an injection that changes every cell. After preparation, the edited cells are infused back into the patient and are meant to establish themselves in the bone marrow.
A result measured in crisis-free months
In the clinical evidence reviewed by the FDA, 29 of 31 evaluable patients did not experience a severe vaso-occlusive crisis for at least 12 consecutive months during the assessment period. That is a specific trial result, not a promise that every person treated will have the same outcome or remain crisis-free indefinitely.
The measure matters because recurrent crises can shape daily life as well as health: they may lead to emergency care, hospital stays and interruptions to work, school or family routines. A period without severe crises is therefore a meaningful early sign of potential benefit. Longer follow-up will help show how durable the effect is and how outcomes vary among patients.
The treatment also builds on decades of research into fetal hemoglobin and the genetic switches that regulate it. CRISPR provides a way to alter a carefully chosen control point in a patient’s cells. Turning that laboratory strategy into an approved therapy required not only a gene-editing tool, but also methods for collecting, processing, testing and returning living cells safely.
A major treatment with a demanding path
Casgevy is not a simple outpatient procedure. Before receiving the edited cells, patients undergo myeloablative chemotherapy to make room in the bone marrow. That conditioning can cause serious side effects and requires specialist care. The FDA’s prescribing information also warns about risks including low blood-cell counts and infection. Patients may need fertility counseling and preservation options before treatment, because conditioning chemotherapy can affect fertility.
The process involves a specialized treatment center, time for cell collection and manufacturing, and a hospital stay for conditioning and infusion. Those practical demands mean that regulatory approval does not automatically make the therapy accessible to everyone who might be eligible. Patients and care teams must weigh the possible benefits against the treatment’s intensity, risks and individual circumstances.
Nor does the approval settle every question. The pivotal results were based on a relatively small group, and continuing monitoring is important for a treatment that changes the genetic material of blood stem cells. The FDA requires long-term follow-up. Further experience can clarify how long benefits last, what additional risks may emerge, and how best to support patients through the treatment pathway.
Why the milestone matters
For years, gene editing was discussed as a powerful technology still seeking a place in everyday medicine. Casgevy’s approval marks a move from possibility to a regulated treatment option for a defined group of people. It also demonstrates a broader idea: medicine can sometimes use a patient’s own cells as both the starting material and the delivery system for a lasting biological change.
That is reason for optimism, with appropriate limits. This therapy is not suitable for every person with sickle cell disease, and it does not erase the need for ongoing care. But for eligible patients facing recurrent severe crises, a treatment designed to help their bodies make more protective hemoglobin offers a new possibility—one built from their own cells and guided by a precise edit.
